INVO Fertility (IVF) EBITDA (2011 - 2025)

INVO Fertility has disclosed EBITDA across 15 years of filings, most recently posting -$1.6 million for Q3 2025.

• Quarterly EBITDA fell 25.88% year-over-year to -$1.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$25.1 million (down 312.85% YoY) and the FY2024 annual result came in at -$8.0 million, down 19.99% from the prior year.
• EBITDA climbed to -$1.6 million in Q3 2025, from -$3.0 million in the prior quarter.
• Across five years, EBITDA topped out at $5.7 million in Q4 2022 and bottomed at -$17.1 million in Q1 2025.
• The 5-year median for EBITDA is -$1.9 million (2021), against an average of -$2.3 million.
• Year-over-year, EBITDA soared 1011.67% in 2022 and sank 1049.64% in 2025.
• INVO Fertility's EBITDA stood at $514987.0 in 2021, then soared by 1011.67% to $5.7 million in 2022, then slumped by 125.98% to -$1.5 million in 2023, then slumped by 131.05% to -$3.4 million in 2024, then surged by 53.32% to -$1.6 million in 2025.
• According to Business Quant data, EBITDA over the past three periods registered -$1.6 million, -$3.0 million, and -$17.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.